Loading...
XASXCTE
Market cap23mUSD
Jan 09, Last price  
0.78AUD
1D
-6.02%
Name

Cryosite Ltd

Chart & Performance

D1W1MN
XASX:CTE chart
P/E
20.69
P/S
3.02
EPS
0.04
Div Yield, %
1.92%
Shrs. gr., 5y
0.82%
Rev. gr., 5y
9.77%
Revenues
13m
+5.67%
2,955,0564,097,1004,722,5726,467,5826,158,3925,968,6016,432,9737,757,5688,497,8039,171,0149,594,37510,043,6745,814,1215,864,1397,911,6958,919,84610,023,76911,756,85011,935,00012,612,000
Net income
2m
+30.59%
-620,311101,374922,744447,0597,2494,612334,3051,022,4791,249,961505,602455,170302,466-142,109-244,696-565,1571,480,179652,5741,363,8311,409,0001,840,000
CFO
3m
+94.69%
-199,902-203,024697,651888,268709,858977,6571,419,3541,880,2121,939,6711,584,9891,416,902474,6081,626,789-261,906-647,5361,306,382476,9652,494,8791,488,0002,897,000
Dividend
Sep 06, 20240.02 AUD/sh
Earnings
Feb 20, 2025

Profile

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.
URL
https://www.cryosite.com/
IPO date
May 09, 2002
Employees
25
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
12,612
5.67%
11,935
1.52%
11,757
17.29%
Cost of revenue
9,771
9,760
9,311
Unusual Expense (Income)
NOPBT
2,841
2,175
2,446
NOPBT Margin
22.53%
18.22%
20.80%
Operating Taxes
246
166
443
Tax Rate
8.66%
7.63%
18.10%
NOPAT
2,595
2,009
2,003
Net income
1,840
30.59%
1,409
3.31%
1,364
108.99%
Dividends
(732)
(488)
Dividend yield
1.21%
1.60%
Proceeds from repurchase of equity
(2,441)
117
BB yield
4.03%
-0.38%
Debt
Debt current
179
161
233
Long-term debt
4,711
4,890
1,233
Deferred revenue
10,925
12,539
14,171
Other long-term liabilities
1,083
1,104
1,128
Net debt
187
(680)
(3,911)
Cash flow
Cash from operating activities
2,897
1,488
2,495
CAPEX
(452)
(301)
(863)
Cash from investing activities
727
(1,331)
(863)
Cash from financing activities
(3,473)
(768)
(149)
FCF
2,921
377
1,748
Balance
Cash
4,703
5,731
5,341
Long term investments
36
Excess cash
4,072
5,134
4,789
Stockholders' equity
1,449
2,782
1,861
Invested Capital
14,453
16,249
16,149
ROIC
16.90%
12.40%
11.76%
ROCE
17.87%
11.43%
13.58%
EV
Common stock shares outstanding
48,810
48,810
48,810
Price
1.24
98.40%
0.63
-0.79%
0.63
 
Market cap
60,524
98.40%
30,506
-0.79%
30,750
 
EV
60,711
29,826
26,839
EBITDA
2,841
2,871
3,010
EV/EBITDA
21.37
10.39
8.92
Interest
163
65
81
Interest/NOPBT
5.74%
2.99%
3.33%